重组人CTLA4Ig融合蛋白体外对人T淋巴细胞功能的影响  

Effects of rhCTLA4Ig on human T lymphocyte in vitro

作　　者：周倩[1] 钱卫珠[1] 寇庚[1] 王皓[1] 刘彦君[1] 李晓冬[1] 吴孟超[2] 郭亚军[1] 陈列平[1] 

机构地区：[1]第二军医大学国际合作肿瘤研究所,上海200433 [2]第二军医大学东方肝胆外科研究所,上海200433

出　　处：《中国药理学通报》2002年第2期165-168,共4页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金资助课题 No 3 992 80 12

摘　　要：目的　研究重组人CTIA4Ig对人T淋巴细胞功能的影响。方法　采用初次混合淋巴细胞培养、再次混合淋巴细胞培养及细胞毒实验的方法。结果　CTLA4Ig在浓度高于3mg·L-1时能有效地抑制初次混合淋巴细胞反应 (P <0 0 5 ) ,其在作用 2 4h内不能发挥有效的抑制作用 ,72h能达最大抑制效率 ;在再次混合淋巴细胞反应实验中CT LA4Ig作用后的T淋巴细胞对同一供者的外周血单核细胞的刺激表现出特异性无反应 ,而对无关供者的外周血单核细胞的刺激能产生正常的应答反应。结论　CTLA4Ig在体外能抑制T细胞的增殖 。AIM To study the effect of rhCTLAIg on human T lymphocytes. METHODS Primary mixed lymphocyte reaction (MLR), secondary MLR and cytotoxicity assay were used. RESULTS CTLA4Ig significantly inhibited primary MLR( P< 0 05) and the maximal inhibition was achieved at 72 h of incubation with CTLA4Ig. Secondary MLR experiment showed cells primed in the presence of CTLA4Ig had a specific hyporesponsiveness when challenged with PBMC from the original donor, yet responded normally to PBMC from the third party donor. CONCLUSIONS CTLA4Ig can inhibit T cell proliferation and induce T cell anergy in vitro by blocking B7/CD28 co stimulatory pathway.

关 键 词：CTLA4IG 人T细胞 混合淋巴细胞反应 

分 类 号：R－332[医药卫生] R329.2